Colorectal carcinoma is the third most common cancer in the United States. Proper and standardized pathologic staging is vital for prognostic assessment and impacts therapeutic decisions. The Tumor Node Metastasis (TNM) staging system was developed by the American Joint Committee on Cancer (AJCC) to be a data-driven, evidence-based staging system providing an accurate prediction of outcome. The AJCC 7th edition (2010) included several changes clarifying some issues and leading to new controversies. We aim to address selected challenging issues in tumor T staging, neoadjuvant treatment effects in rectal cancer, and definition of lymph node vs tumor deposit. Serosal involvement in colorectal cancer is staged as T4, which is associated with decreased survival and may impact additional therapy decisions. Although careful sampling and sectioning are helpful, challenges remain in interpretation of tumor within 1 mm of serosal surface with a reaction. Elastic stain as a surrogate marker for serosal invasion has been studied, but its usefulness remains unclear. Some unique issues in rectal cancer include the presence of serosa in proximal but not in distal tumors and post-neoadjuvant effects. Tumor should be staged based on tumor cells rather than acellular mucin pools. Additionally, tumor response should be graded only in primary tumor but not in lymph nodes or metastatic sites. The distinction between tumor deposits and lymph nodes has been modified in AJCC TNM from using size in the 5th edition, to the round contour in the 6th edition, to only features of residual lymph node architecture in the 7th edition. Interobserver variability remains but tumor deposits should be documented when present. The number of deposits should not be added to the total number of positive lymph nodes, and the N1c designation should only be used in cases without any positive lymph nodes. Future clarification will likely evolve as more data become available.
Colorectal carcinoma (CRC) is the third most common cancer in the United States. 1, 2 According to National Cancer Institution Surveillance, Epidemiology, and End Results Program (SEER) Stat Fact Sheets, it is estimated that there will be B140 000 new cases and greater than 50 000 deaths in 2014 in the United States. Pathologic assessment is the gold standard for determining local extent of disease, and is vital for prognosis and decisions regarding need for adjuvant therapy and entrance to clinical trials. The strongest predictor of survival is pathologic staging. Other important morphologic prognostic factors include tumor type and margin assessment. Stage-independent factors include lymphvascular and perineural invasion, tumor border configuration, tumor budding, host lymphoid response, and morphologic features suggestive of microsatellite instability. 3 A number of challenges and caveats exist in the pathologic staging and reporting of CRC. 4, 5 In this article, we focus on selected issues in tumor T staging, neoadjuvant treatment effects in rectal cancer, and the definition of lymph node vs tumor deposits. The Tumor Node Metastasis (TNM) staging system was developed by the American Joint Committee on Cancer (AJCC) to be a data-driven, evidence-based cancer staging system providing an accurate prediction of outcome. As new evidence is acquired, frequent updating of staging is essential. The AJCC Cancer Staging Manual 7th edition, released in 2010, included several changes clarifying some issues and leading to new controversies. 3 The College of American Pathologists (CAP) checklist was recently updated at the CAP website in October 2013.
Tumor T staging
The T category of the TNM staging system is divided into Tis, T1, T2, T3, and T4 depending on depth of tumor invasion and extension into adjacent organs/ structures (Table 1) . Tis is tumor limited to the muscularis mucosa, T1 lesions are limited the submucosa, T2 lesions are limited to the muscularis propria, T3 lesions extend beyond the muscularis propria into the pericolonic adipose tissue, and T4 lesions penetrate the serosa and/or extend into adjacent organs/structures. T3 tumors in some studies have been subdivided, but this subdivision has not been accepted in the United States or AJCC Cancer staging manual. T4 tumors are divided into T4a and T4b.
Serosal Involvement
One of the most controversial areas in T staging is the distinction between deep T3 and T4a tumors. This distinction is not only important for helping to predict prognosis, but is also vital for some treatment decisions. Patients with Stage II tumors (lymph node negative) do not typically get treated with adjuvant chemotherapy, while patients with Stage III and IV tumors do. It has been suggested by the American Society of Clinical Oncology (ASCO) that the routine use of adjuvant chemotherapy is not recommended for patients with Stage II colon cancer, but there are some patient populations to consider for adjuvant chemotherapy, such as those with inadequately sampled nodes, T4 tumors, bowel perforation, or poorly differentiated histology. 6 The National Comprehensive Cancer Network (NCCN) Guidelines (Version 2.2014) characterize high-risk factors for systemic recurrence as poorly differentiated histology (not MSI-H), lymphatic/vascular invasion, perineural invasion, o12 lymph nodes identified in colon cancer, bowel obstruction, localized perforation, and close, indeterminate or positive margins. Therefore, a patient with a pT3N0 cancer will likely not get adjuvant chemotherapy, while a patient with pT4N0 cancer may be treated with adjuvant chemotherapy.
There has been significant variability in reporting serosal involvement. [7] [8] [9] Studies with meticulous sampling including multiple sections of tumor and step sections in most concerning areas have shown high rate (59%) of serosal involvement. Other studies have shown much lower rates of involvement. In a study by Shepherd et al 8 with meticulous sampling of 412 colon cancers, histological assessment of local peritoneal involvement was described as follow: tumor well clear of closest peritoneal surface (LP1, 20%); mesothelial inflammatory and/or hyperplastic reaction with tumor close to, but not at the peritoneal surface (LP2, 22%); tumor present at the peritoneal surface with inflammatory reaction, mesothelial hyperplasia, and/or ulceration (LP3, 27%); and tumor cells shown free in peritoneum and evidence of adjacent ulceration (LP4, 32%). The results from Shepherd's group 8, 9 and a recent study 10 suggested that peritoneal involvement is the parameter with the strongest independent prognostic significance and is even more powerful than the extent of local spread or lymph node involvement. Serosal involvement is thought to be underdiagnosed in up to 20% of cases called T3 rather than T4a, likely due to inadequate sampling and not recognizing serosal penetration.
Step sections or more sampling can be helpful in some cases. Histological parameters to identify these features are not always entirely straightforward and the absence of standard guidelines for assessing peritoneal involvement is felt to likely contribute to underdiagnosis. 11 If tumor is seen close to the surface, then we evaluate deeper levels and may regross the tumor to take more sections before classifying as T4 (Figure 1a-d) . Also, serosal clefts may contain tumor cells and are important to evaluate (Figure 1e and f) .
The following findings are suggested by CAP to be considered to represent serosal involvement by tumor and are associated with decreased survival: tumor present at the serosal surface with inflammatory reaction, mesothelial hyperplasia, and/or erosion/ulceration; and free tumor cells on the serosal surface (in the peritoneum) with underlying ulceration of the visceral peritoneum. A mesothelial inflammatory and/or hyperplastic reaction with tumor close to, but not at, the serosal surface is currently not included in CAP protocol. This type of local peritoneal reaction remains controversial. A recent study by Panarelli et al 12 using serosal scrape cytology in 128 cases of colon cancer showed that peritoneal cytology was positive in 19% T3 (46% in T3 within 1 mm of serosal reaction) and 55% T4 tumors. Additionally, when tumor was within 1 mm of the serosal surface, frequent reactive findings LPI3/LPI4) but not LPI2 (reaction with tumor close to, but not at the peritoneal surface) should be considered T4a. Figure 2 shows challenging cases of tumor with associated fibroinflammatory reaction and peritumoral abscess close to but not at serosal surface.
Since mesothelial cells can be inconspicuous in routine hematoxylin and eosin (H&E) stain, ancillary stains such as the cytokeratin 7 immunohistochemical stain have been considered to help to recognize mesothelial cells ( Figure 3 ). However, Liang et al demonstrated that cytokeratin 7 only highlighted mesothelial cells in 27 of 168 colorectal cancer cases tested, and only helped the identification of serosal invasion in 5 cases (3%). 3 They thus suggested that cytokeratin 7 was not very useful in this purpose.
Elastic Stain to Identify Elastic Lamina Invasion
Since the distinction between T3 and T4a tumors can be challenging by histology alone, the elastic stain has been investigated to assess invasion of the elastic lamina as a surrogate for serosal surface invasion. [13] [14] [15] [16] The elastic stain is useful in assessing involvement of the visceral peritoneum in lung cancers, and is used in AJCC TNM 7th edition to help stage lung cancers. The subserosal elastic lamina is located just deep to the peritoneum in the colon. Studies have varied in terms of the stain used and number of sections stained (Table 2) . Grin et al 14 recently evaluated 217 cases and found that disease-free survival was not significantly different between T3 tumors with and without elastic lamina invasion. Furthermore, they found that disease-free survival was significantly shorter in patients with T4 tumors than those with T3 with or without invasion of the elastic lamina. Additionally, only 28% of cases showed strong and continuous staining of the elastic lamina. In contrast, three other studies have shown that survival was significantly shorter in those with elastic lamina invasion than those without invasion, 13, 15, 16 and two of these reported survival in some subsets of cases more similar to T4 lesions than T3 without elastic lamina invasion. However, in Liang's study, the elastic lamina was only evaluable in 41% of cases. 13 They concluded that this did not seem to be a major problem because prognosis was similar in those with no elastic lamina identified to those without elastic lamina invasion. Kojima et al 15 stained an average of 4.6 slides per case in order to be able to interpret almost all cases (10, T4 cases could not be evaluated for elastic lamina invasion) while Liang et al 13 only stained 1 slide per case.
Many questions remain for using elastic stain to identify elastic lamina invasion in colon cancer. [17] [18] [19] In some cases, clear-cut invasion by tumor cells can be identified (Figures 4a and b) . The elastic lamina is not present in all cases, particularly in the right colon, and can be difficult to interpret in some cases 14 (Figures 4c and d) . It is frequently incomplete or retracted toward tumor in cases with a reaction where its use may be most necessary. Also, the use of the stain is not practical if it is necessary to stain greater than one slide for adequate interpretation. Additionally, data are not conclusive as to how to report results (upstage or add comment) if you find elastic lamina invasion in a deep T3 tumor. The use of elastic stains or other surrogate markers for serosal invasion is not currently recommended in the AJCC 7th edition. Our experience is that deeper sections are more often useful than using this surrogate marker ( Figure 5 ).
T4 Subdivisions
T4 tumors are currently divided into T4a and T4b lesions. Previously, studies suggested that serosal involvement was associated with a worse outcome than direct invasion of adjacent organs. 8, 20, 21 Therefore, AJCC TNM 6th edition supplement categorized T4a as invasion of adjacent organs and T4b as invasion of the serosa. 22 Recently, a larger study showed that penetration of the visceral peritoneum had a better 5-year survival than local invasion into adjacent organs. 23 AJCC TNM 7th edition now categorizes T4a as serosal involvement and T4b as local invasion of adjacent organs or structures. 3 To classify a tumor as T4b, adhesion to an adjacent structure is not sufficient; tumor cells must be seen in the adhesion. Adhesions without tumor cells should not be used to classify as T4b ( Figure 6 ).
Staging rectal tumors can be confusing, and a common misconception is that rectal tumors can never be classified as T4a. 24, 25 However, in peritonealized portions of the rectum (proximal), tumor can be staged as T4a. In the distal rectum, there is no peritoneal surface, therefore, a positive radial surface would make the tumor T3 R1 (microscopic involvement) or R2 (macroscopic involvement).
Neoadjuvant treatment effects in rectal cancer
Neoadjuvant chemoradiation is typically used for advanced rectal cancers that are T3 or T4 and/or lymph node positive. Patients are treated before the Figure 4 The use of elastic stains to evaluate elastic lamina invasion. H&E stain shows tumor cells (arrow head) close to but not at the serosal surface (a, Â 100); Elastic stain shows tumor (arrow head) with elastic lamina invasion (arrow) (b, Â 100). However, elastic stain can be difficult to interpret (c, Â 100; arrow points to possible elastic lamina), or incomplete (d, Â 100; arrow points to incomplete elastic lamina).
resection, and postoperatively, all receive adjuvant chemotherapy regardless of the lymph node status after resection. The assessment of residual carcinoma is important and likely has direct bearing on prognosis. 25, 26 Abdul-Jalil et al 27 recently showed that complete response, nodal status, and circumferential resection margin but not tumor regression grade predicted long-term survival in their series of 153 rectal cancer patients. The prefix y should be used in staging these cases. Neoadjuvant treatment effects that are commonly seen include acellular mucin pools in the rectal wall and lymph nodes and tumor regression. Acellular mucin should not be used to upstage T or N stage. In cases with mucin pools, residual carcinoma should be diagnosed only in those with residual and morphologically viable neoplastic cells within the mucin pools. Similarly, margin or lymph nodes with mucin are considered positive only when the mucin pools contain malignant cells (Figure 7) . Level sections may be helpful in some cases. However, controversy remains for the definition of residual viable tumor. Shia et al 5 suggested that a treated rectal cancer may show residual tumor cells in different stages of degeneration, and they may not be entirely equivalent to tumor cells of untreated cases. Until better definitions become available, it is recommended that the tumor cell viability can be determined based on whether the nuclear details of the cells are discernible. Tumor regression grade is determined by the evaluation of the primary tumor and not metastases in lymph nodes or other sites (Figure 8 ). There are several grading scales available, but interobserver agreement is overall poor. 28 The pathologic response to treatment should be graded as the tumor regression grade. Table 3 shows the grading in AJCC 7th edition. 3 
Lymph node issues

Tumor Deposits
Many studies have shown that tumor deposits are associated with higher tumor stage and overall poor prognosis. [29] [30] [31] [32] [33] [34] [35] However, the outcome data are still complicated and confusing due to different definitions of tumor deposits. One of the most significant and controversial changes in staging CRC in the AJCC 7th edition is in the definition of tumor deposits, and the role these deposits play in staging and prognosis. In cases where no definite lymph nodal architecture remains, the distinction of a tumor deposit from involved lymph node has progressed from a reliance on size of 3 mm (5th edition, 1997), 36 to contour (6th edition, 2002), 22 to only features of residual lymph node architecture (7th edition, 2010) ( Figure 9 ; Table 4 ). 3 Concurrently, the role of tumor deposits in staging has moved from its prior involvement in the T category (5th/6th) to the development of a new nodal subcategory, N1c (7th). In AJCC 5th edition, tumor nodules less than 3 mm in size without residual lymph node were considered discontinuous extension and when necessary the T stage was upstaged. In Figure 5 Deeper sections may be more useful than elastic stain in evaluating serosal involvement. H&E section shows tumor cells are close to but not at the serosal surface (a, Â 100); deeper H&E section shows tumor with necrosis on the serosal surface (T4a) (b, Â 100); while the elastic stain does not show elastic lamina invasion (c, Â 100, arrow points to elastic lamina). AJCC 6th edition, irregular tumor nodules without residual lymph nodes were classified in the T category and also coded as V1 or V2.
As specified in the AJCC 7th edition, pericolonic tumor deposits are 'discrete foci of tumor found in the pericolic or perirectal fat or in adjacent mesentery (mesocolic fat) away from the leading edge of the tumor and showing no evidence of residual lymph node tissue.' 3 The previous size and shape criteria used for the distinction were largely arbitrary and not evidence based using outcome data. The size criterion was more objective than the contour criterion, but the outcome data were not confirmed. The new category of N1c was created to allow data collection and outcome analysis to be performed in the hopes of better understanding the clinical significance of tumor deposits. Since no definite criteria are provided to distinguish tumor deposits from totally replaced lymph nodes, the differential remains challenging in some cases where it is difficult to decide whether residual lymph node architecture exists. 37 Interobserver variability remains even when evaluated by pathologists with an interest in gastrointestinal pathology. 37 (Figure 10 ). The helpful features of residual lymph node include round shape, peripheral lymphocytes/follicles, thick capsule, and possible subcapsular sinus.
Additionally, there remains confusion with the use of the current definition and new category of N1c. It is important to remember that tumor deposits should only be diagnosed when there is no residual In some cases, it is difficult to determine whether a tumor deposit near the leading edge of the tumor should be called a tumor deposit or considered discontinuous spread. Deeper sectioning can sometimes be helpful in this distinction. 38, 39 There is not a definite 'distance rule' for what can be considered a tumor deposit. Ueno et al 34 studied 695 colorectal cancer patients and evaluated tumor deposits greater than or equal to 2 mm from the leading edge of the cancers. They found, in multivariate analysis, that the presence of tumor deposits had an adverse survival impact independent of T and N stage. Furthermore, the distance from the tumor to the deposit (if greater than 2 mm) did not affect prognosis. Figure 11 shows cases where the tumor nodule is within 1 mm from the leading edge of the tumor. In cases where deeper sections demonstrate continuous nests of tumor (Figure 11a ), the tumor nodule is best not considered as a tumor deposit. When there is no clear connection and the nodule appears discrete (Figure 11b-d) , we consider the tumor nodule a tumor deposit.
Required Number of Lymph Nodes
It is clear in the literature that as many lymph nodes as possible should be evaluated to determine the N stage. [40] [41] [42] [43] [44] Fat clearing does help in some cases, but is not required and is not the standard of care in most institutions. AJCC TNM 7th edition requires at 3 while CAP suggests regrossing when less than 12 nodes are identified. 45, 46 Even if less than the suggested number of lymph nodes is identified, then the tumor should still be given an N stage rather than designated Nx. It has been shown that many factors affect lymph node recovery including the experience/diligence of the surgeon and grossing pathologist; patient age, gender, body habitus, immune response; and tumor site, size and length of colon resected. Additionally, the current classification of deposits that were previously called lymph nodes as tumor deposits has caused a reduction in the number of lymph nodes harvested in some cases. Several recent papers have suggested the usefulness of the lymph node ratio rather than the total number of involved lymph nodes. [47] [48] [49] [50] This is not currently recommended but is an issue that may be considered for staging in the future.
There is no minimum number of lymph nodes suggested for rectal cancer after neoadjuvant chemoradiation therapy. As many lymph nodes as possible should still be evaluated, however, it has been shown that the number of lymph nodes is reduced in these cases. 51, 52 A recent study by de Campos-Lobato et al 45 concluded that the identification of less than 12 lymph nodes may be a marker of higher tumor response and decreased local recurrences. They studied 237 patients treated with neoadjuvant chemoradiation followed by total mesorectal excision and compared outcome in those with less than 12 lymph nodes with those with greater than or equal to 12 lymph nodes harvested. No significant differences were seen between the groups in overall survival, cancer-specific mortality, cancer-free survival, and distant recurrences; however, the local recurrences were significantly lower in the less than 12 lymph nodes recovered group. Proper and standardized pathologic staging is vital for prognostic assessment and impacts therapeutic decisions. There remain challenges in uniformity and definition in several areas. It is clear that serosal involvement in colon cancer is underdiagnosed, associated with decreased survival, and may impact additional therapy decisions. Although careful sampling and sectioning are helpful in some cases, challenges remain in the interpretation of surrogate markers for serosal involvement, such as tumor within 1 mm of the serosal surface with a reaction and invasion of the elastic lamina. Some unique issues in rectal cancer include the presence of serosa in proximal tumors and postneoadjuvant effects. It is important to remember that tumor should be staged based on viable tumor cells rather than acellular mucin pools. Additionally, tumor response should be graded only in the primary tumor and not in lymph nodes or metastatic sites. Tumor deposits remain a difficult area but should be documented when present. The number of deposits should not be added to the total number of positive lymph nodes, and the N1c designation should only be used in cases without any positive lymph nodes. AJCC 8th edition will likely address some of these issues leading to some clarification while introducing new challenges.
